A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region

A Phase 4, Open-label Study to Investigate the Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in the Treatment of Plaque Psoriasis Occurring in the Head and Neck Region

This is an open-label, multi-center study to evaluate the efficacy and safety of VTAMA (tapinarof) cream, 1% in adults with plaque psoriasis occurring in the head and neck region

Study Overview

• Status: Completed
• Conditions: Psoriasis
• Intervention / Treatment: Drug: VTAMA (tapinarof) cream, 1%

Detailed Description

This is an open-label study in which participants with plaque psoriasis in the head and neck region will be assigned to receive VTAMA (tapinarof) cream, 1% once daily for 12 weeks. Study participants will have a follow-up period of 1 week. The study duration will be up to 17 weeks.

• Study Type: Interventional
• Enrollment (Actual): 31
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • Georgia
    • Macon, Georgia, United States, 31217
      • Dermavant Investigative Site
  • Illinois
    • Chicago, Illinois, United States, 60602
      • Dermavant Investigative Site
  • Maryland
    • Rockville, Maryland, United States, 20850
      • Dermavant Investigative Sites
  • Michigan
    • Auburn Hills, Michigan, United States, 48326
      • Dermavant Investigative Site
    • Detroit, Michigan, United States, 48202
      • Dermavant Investigative Site
  • Nevada
    • Las Vegas, Nevada, United States, 89144
      • Dermavant Investigative Site
  • New Hampshire
    • Portsmouth, New Hampshire, United States, 03801
      • Dermavant Investigative Site
  • New York
    • Kew Gardens, New York, United States, 11415
      • Dermavant Investigative Site
  • Ohio
    • Marion, Ohio, United States, 43302
      • Dermavant Investigative Site
  • Texas
    • Arlington, Texas, United States, 76014
      • Dermavant Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• 18 years of age or older, at the time of signing the informed consent
• Participants with clinical diagnosis of plaque psoriasis, including lesion(s) in the head and neck region and stable disease in the head and neck region for at least 3 months prior to the study
• Participant has a plaque psoriasis lesion in the head and neck region that is suitable for evaluation as the target lesion and has a PGA (target lesion) score of 2 (Mild), 3 (Moderate), or 4 (Severe) at Screening and Baseline
• Female subjects of child bearing potential who are engaging in sexual activity that could lead to pregnancy agree to follow the specified contraceptive guidance throughout the study
• Negative pregnancy test at Baseline (Day 1)
• Capable of giving written informed consent

Exclusion Criteria:

• Diagnosis of a type of psoriasis other than plaque psoriasis
• Any sign of infection of any of the psoriatic lesions
• Concurrent significant dermatologic or inflammatory condition other than plaque psoriasis that, in the Investigator's opinion, would make it difficult to interpret data or assessments during the study
• History of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the Investigator's opinion, may interfere with participation in the study and ability to understand and give informed consent
• History of sensitivity to the study product, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates participation in the study
• Previous known participation in a clinical study with tapinarof (previously known as GSK2894512 and WBI-1001); previous or current use of VTAMA® (Tapinarof) cream, 1%
• Use of any prohibited medication or procedure within the indicated period before the baseline visit including other investigational product within 30 days or 5 half-lives of the investigational product (whichever is longer)
• UV light therapy or prolonged exposure to natural or artificial sources of UV radiation (e.g., phototherapy, tanning beds/booths, or therapeutic sunbathing) within 4 weeks prior to the Baseline

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: VTAMA (tapinarof) cream, 1%; VTAMA (tapinarof) cream, 1% applied topically once daily	Drug: VTAMA (tapinarof) cream, 1%; VTAMA (tapinarof) cream, 1% applied topically once daily; Other Names: DMVT-505

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Who Achieve a Target Lesion Physician Global Assessment (PGA) Score in the Head and Neck Region of Clear (0) or Almost Clear (1) With a ≥ 2-grade Improvement	Physician Global Assessment (PGA) is a clinical tool for assessing the current state/severity of a participant's psoriasis in a target lesion of the head and neck region at a given timepoint. It is a static 5-point assessment of plaque qualities on the clinical characteristics of erythema, scaling, and plaque thickness/elevation within the head and neck region. The PGA ranges from 0 to 4, and is assessed as Clear (0), Almost Clear (1), Mild (2), Moderate (3), and Severe (4). Higher PGA scores represent more severe disease.	from Baseline to Week 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to Achieve a Target Lesion PGA Score of Clear (0) or Almost Clear (1) With a ≥ 2-grade Improvement	Physician Global Assessment (PGA) is a clinical tool for assessing the current state/severity of a participant's psoriasis in a target lesion of the head and neck region at a given timepoint. It is a static 5-point assessment of plaque qualities on the clinical characteristics of erythema, scaling, and plaque thickness/elevation within the head and neck region. The PGA ranges from 0 to 4, and is assessed as Clear (0), Almost Clear (1), Mild (2), Moderate (3), and Severe (4). Higher PGA scores represent more severe disease.	Baseline to Week 12

Collaborators and Investigators

• Sponsor: Organon and Co
• Investigators: Study Director: Philip Brown, MD, JD, Chief Medical Officer, Dermavant Sciences, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): March 13, 2023
• Primary Completion (Actual): June 30, 2023
• Study Completion (Actual): July 19, 2023

Study Registration Dates

• First Submitted: March 14, 2023
• First Submitted That Met QC Criteria: March 16, 2023
• First Posted (Actual): March 29, 2023

Study Record Updates

• Last Update Posted (Actual): June 12, 2025
• Last Update Submitted That Met QC Criteria: May 30, 2025
• Last Verified: August 1, 2024

More Information

Terms related to this study

• Keywords: Safety; Psoriasis; Efficacy; Open-label; Adult; Plaque Psoriasis; Scalp Psoriasis; Topical; Phase 4; Tapinarof; Face Psoriasis; Neck Psoriasis; Psoriatic conditions
• Additional Relevant MeSH Terms: Skin Diseases, Papulosquamous; Skin Diseases; Psoriasis
• Other Study ID Numbers: DMVT-505-4002

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No